Ogsiveo (nirogacestat) — CareFirst (Caremark)
Progressing desmoid tumors that require systemic treatment
Initial criteria
- Authorization of 12 months may be granted for treatment of progressive, morbid, or symptomatic desmoid tumors as a single agent
Reauthorization criteria
- Authorization of 12 months may be granted for continued treatment when there is no evidence of unacceptable toxicity or disease progression while on the current regimen
Approval duration
12 months